# Determining the Mechanism of RAN Translation in C9orf72-Associated ALS/FTD

> **NIH NIH F31** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 · $39,354

## Abstract

Abstract
The most common known genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia
(FTD) is a G4C2 hexanucleotide repeat expansion in the first intron of the C9orf72 gene. This repeat undergoes
a non-canonical form of protein translation initiation known as repeat associated non-AUG (RAN) translation
(RANT). RANT initiates from non-AUG codons and in C9orf72-associated ALS/FTD (C9ALS/FTD) produces
dipeptide repeat proteins (DPRs) that aggregate within inclusions in patient brains. DPR expression separate
from potentially toxic repeat-containing RNA species is sufficient to induce cell death and reduce cell viability in
many model systems, including primary mammalian neurons. As such, RANT is thought to contribute to
disease pathogenesis. Despite this central importance, the exact endogenous repeat-containing transcripts
from which DPRs are translated remains unknown. The repeat is located within the first intron and typically,
introns are spliced from pre-mRNA as RNA lariats and rapidly degraded. In C9ALS/FTD, repeat RNAs are
observed in the cytoplasm and undergo translation. Initial studies suggested that RANT could occur from a
linear mRNA in which the repeat-containing intron is retained or via internal ribosomal entry from a C9orf72
lariat that fails to undergo degradation. However, our group recently identified a third potential source template
for C9RANT: repeat triggered transcriptional initiation within the first intron itself that generates capped repeat
containing mRNAs. This proposal will determine the RNA templates that undergo C9RANT in patient neurons
and whether targeting pathways which influence their production and stability are capable of modulating RANT
production and suppressing toxicity in C9ALS/FTD patient-derived iNeurons. Using patient-derived neurons, I
will determine the molecular nature of repeat containing C9orf72 transcripts that undergo RANT using
polysome profiling, qRT-PCR, and hybridization chain reaction coupled with confocal microscopy and
biochemical assays. In parallel, I will develop antisense oligonucleotides (ASOs) that selectively target this
novel C9orf72 transcript and determine the impact of modulating C9orf72 splicing and RNA species production
on C9RANT generation and repeat toxicity. The training described in this proposal will prepare me to work at
the interface between cellular and molecular neurobiology and its application towards patient-oriented
therapeutics.

## Key facts

- **NIH application ID:** 10462011
- **Project number:** 1F31NS127371-01
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Shannon Lynne Miller
- **Activity code:** F31 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $39,354
- **Award type:** 1
- **Project period:** 2022-05-01 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10462011

## Citation

> US National Institutes of Health, RePORTER application 10462011, Determining the Mechanism of RAN Translation in C9orf72-Associated ALS/FTD (1F31NS127371-01). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10462011. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*